Clinical trial
Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine
NCT05768126 is registered in ClinicalTrials.gov with UMC Utrecht as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine
- Lead sponsor
- UMC Utrecht
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- September 29, 2021
- Completion date
- January 31, 2026
- Enrollment
- 100 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.